HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Indoco Remedies Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 85 filings·Updated 7 Oct 2026
Showing 10 of 85 filings.
7 Oct 20261 filing
Company UpdateCertificate under SEBI (Depositories and Participants) Regulations, 2018

Indoco Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 14:15View Source
29 Sept 20262 filings
Company UpdateGeneral

Indoco Remedies informs physical shareholders to update PAN, KYC, and bank details per SEBI circular

Regulatory update for physical shareholders

  • SEBI circular requires PAN, KYC, mobile, signature, and bank details for physical holders.
  • Dividends for physical folios will be paid electronically from April 1, 2024.
  • Transfer of physical shares is not permitted since April 1, 2019.
  • MUFG Intime India Private Limited is the RTA for updating details.
  • Forms ISR-1, ISR-2, ISR-3, SH13, SH14 are available on the MUFG site.
  • Email registration is optional but enables online services and nominations.
  • Current folio statuses are provided for reference and to enable compliance.
  • Dematerialisation process steps include opening a demat account and engaging a DP.
  • RTA contact details and investor helpdesk are provided for queries.
Filed 16:06View Source
Company UpdateGeneral

Indoco Remedies informs physical-shareholders to update PAN, KYC and bank details per SEBI circular

Physical-shareholder KYC update

  • SEBI circular requires physical-holding shareholders to furnish PAN, KYC, mobile, signature, and bank details.
  • MUFG Intime India Private Limited is the RTA managing updates; forms are on their site.
  • Dividends to be paid electronically per SEBI LODR Fifth Amendment Regulations 2025.
  • Transfer of physical shares prohibited since 2019; dematerialisation encouraged.
Filed 15:57View Source
28 Sept 20263 filings
Company UpdateAcquisition

Indoco Remedies to form 100% owned Indian pharma subsidiary Warren Lifesciences

WLPL incorporation

  • Target: Warren Lifesciences Private Limited (WLPL), a newly incorporated Indian pharmaceutical entity.
  • Authorized share capital Rs 1,00,000; 10,000 equity shares of Rs 10 each.
  • Indoco to hold 100% of WLPL's paid-up capital.
  • Cash consideration for 10,000 WLPL shares at Rs 10 each.
  • Incorporated in India on 26 September 2026; yet to commence business.
  • WLPL will manufacture, develop, and sell APIs, finished formulations, and key starting materials.
  • WLPL is a wholly owned subsidiary and related party of Indoco Remedies Limited.
  • Background: India-incorporated WLPL, registered in Mumbai; hasn't commenced business; no turnover history yet.
  • Industry: pharmaceutical sector.
Filed 21:20View Source
Company UpdateAcquisition

Indoco Remedies forms wholly owned Warren Lifesciences Private Limited to manufacture pharmaceuticals in India

Target overview

  • Warren Lifesciences Private Limited (WLPL) is the target entity in pharma, India.
  • WLPL authorised capital Rs 1,00,000; 10,000 shares of Rs 10 each.

Ownership and related party

  • WLPL is a wholly owned subsidiary; Indoco holds 100% stake.
  • WLPL is a related party of Indoco Remedies.

Purpose and business

  • Object to manufacture, develop, sell APIs, formulations, and key starting materials.

Regulatory and approvals

  • No approvals required for incorporation.

Financials and consideration

  • Cost of acquisition: Rs 1,00,000; cash consideration for 100% stake.
  • 10,000 WLPL equity shares subscribed at Rs 10 per share.

Background and timeline

  • WLPL incorporated in India on 26 September 2026; yet to commence business.
  • Indoco to subscribe for 100% of WLPL's paid-up capital.
Filed 20:58View Source
Insider Trading / SASTClosure of Trading Window

Indoco Remedies Ltd: Trading Window closed from 1 October 2026 until 48 hours after declaration of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30 September 2026.

Indoco Remedies Ltd: Trading Window closed from 1 October 2026 until 48 hours after declaration of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30 September 2026.

Filed 14:45View Source
18 Sept 20263 filings
Company UpdateAcquisition

Indoco to form wholly owned Warren Lifesciences Private Limited in India for pharma manufacturing

Target overview

  • Target: Warren Lifesciences Private Limited to be incorporated as a wholly owned subsidiary of Indoco Remedies.
  • Industry: Pharmaceutical sector; India-based operations.
  • Purpose: Manufacture, develop, and sell APIs, finished formulations, and key starting materials.
  • Capital: Authorized Rs 100,000; paid-up Rs 100,000; 10,000 shares of Rs 10 each.
  • Shareholding: Indoco to hold 100% equity in Warren Lifesciences Private Limited.
  • Consideration: Cash for subscribing to equity shares.
  • Price: Rs 10 per share (face value).
  • Regulatory: ROC/MCA approvals and other regulatory clearances.
  • Timeline: Incorporation to be completed in due course; date to be intimated.
  • Background: Pharma product manufacturing focus; incorporation pending.
  • Status: 100% ownership by Indoco; no external promoter stake.
  • Turnover: Not disclosed.
Filed 18:01View Source
Company UpdateAcquisition

Indoco Remedies to form wholly owned subsidiary Warren Lifesciences Private Limited in India

Subsidiary formation

  • Target: Warren Lifesciences Private Limited, to be incorporated in India as a wholly owned subsidiary.
  • Industry: Pharmaceutical sector; products include APIs, finished formulations, and key starting materials.
  • Funding: Cash consideration; shares subscribed at face value of Rs 10 per share.
  • Capital structure: Authorized and paid-up capital of Rs 1,00,000 comprising 10,000 equity shares.
  • Shareholding: Indoco Remedies Limited will hold 100% of Warren Lifesciences.
  • Regulatory approvals: Incorporation subject to ROC/MCA and other statutory approvals.
  • Timeline: Date of incorporation will be intimated; no completion date specified.
  • Purpose: Expand pharmaceutical manufacturing capabilities within the group.
  • Background: Proposed company yet to be incorporated, India-based focus on APIs and formulations.
Filed 17:56View Source
AGM/EGMAGM

Indoco Remedies' 79th AGM held via VC/OAVM; final dividend approved and MD reappointment with dissent

AGM details

  • AGM held on 17 September 2026 at 10:30 IST via VC/OAVM.
  • Remote e-voting window: 13–16 September 2026; cut-off date 10 September 2026.

Key resolutions and results

  • Item 1 (Ordinary): Standalone financials adopted; 99.99% in favour; passed.
  • Item 2 (Ordinary): Consolidated financials adopted; 100% in favour; passed.
  • Item 3 (Ordinary): Final dividend of ₹0.20 per share; 99.94% in favour; passed.
  • Item 4 (Ordinary): Re-appointment of Aditi Panandikar by rotation; 99.94% in favour; passed.
  • Item 5 (Ordinary): Cost Auditors remuneration for FY 2026-27 ratified; 100% in favour; passed.
  • Item 6 (Special): Re-appoint Aditi Panandikar as Managing Director; 85.73% in favour; passed.
  • Item 7 (Special): Continuation of Vasudha Kamath as NED post-75 years; 94.37% in favour; passed.
  • Item 8 (Special): Borrowing limits increased; 99.96% in favour; passed.
  • Item 9 (Special): Sell/charge on assets; 99.44% in favour; passed.

Dividend

  • Final dividend approved: ₹0.20 per equity share.

Directors & management changes

  • Re-appointment of Aditi Panandikar as Director by rotation; approved.
  • Re-appointment of Aditi Panandikar as Managing Director; approved.

Auditors and remuneration

  • Remuneration of Cost Auditors for FY 2026-27 ratified.

Financing and asset encumbrance

  • Borrowing limits increased under Section 180(1)(c); approved.
  • Approval to create mortgage or charge on assets; approved.
Filed 13:28View Source
17 Sept 20261 filing
AGM/EGMAGM

Indoco Remedies AGM 2026 held via VC; dividend proposal and governance resolutions placed, voting results not disclosed

AGM details

  • Date and time: 17 September 2026, 10:30 a.m.; mode: VC/OAVM.
  • Quorum confirmed through VC; meeting commenced.
  • Meeting concluded at 11:48 a.m. (including 30 minutes for e-voting).

Key resolutions and voting

  • Resolution 1 (Ordinary): Adopt standalone financial statements; voting results not disclosed.
  • Resolution 2 (Ordinary): Adopt consolidated financial statements; voting results not disclosed.
  • Resolution 3 (Ordinary): Final dividend proposal of Rs 0.20 per equity share; voting results not disclosed.
  • Resolution 4 (Ordinary): Re-appoint Ms. Aditi Panandikar as Director; voting results not disclosed.
  • Resolution 5 (Special): Ratify remuneration of Cost Auditors for FY 2026-27; voting results not disclosed.
  • Resolution 6 (Special): Re-appoint Ms. Aditi Panandikar as Managing Director; voting results not disclosed.
  • Resolution 7 (Special): Continue Dr. Vasudha V Kamat as Non-Executive Independent Director after 75th birthday; voting results not disclosed.
  • Resolution 8 (Special): Approve increase in borrowing limits under Section 180(1)(c); voting results not disclosed.
  • Resolution 9 (Special): Approve sale, mortgage or charge on assets under Section 180(1)(a); voting results not disclosed.
Filed 13:14View Source
Showing 10 of 85 filings